A study of atenolol and nebivolol in prehypertension


  • Raj Kumar Arya Department of Pharmacology, Gajara Raja Medical College, Gwalior, Madhya Pradesh, India
  • Dinesh K. Jain Department of Pharmacology, Bundelkhand Medical College, Sagar, Madhya Pradesh, India


Atenolol, Nebivolol, Prehypertension, Mean systolic blood pressure, Mean diastolic blood pressure


Background: Patients with prehypertension have an increased risk of cardiovascular disease. The coexistence of prehypertension with risk factors increases cardiovascular morbidity and mortality. That’s why it is important to treat pre-hypertensive patients having risk factors. The objective was to evaluate the effect of atenolol and nebivolol in pre-hypertensive patients.

Methods: Pre-hypertensive patients having risk factors were selected, and non-pharmacological therapy was advised to all patients. Those patients who were not able to follow strictly non-pharmacological guidelines and remained pre-hypertensive were included in this study. Pre-hypertensive patients were divided into three groups. One group received atenolol 50 mg orally, once daily. Second group received nebivolol 5 mg orally, once daily. Third group received placebo orally, once daily. All groups received treatment for 1 month.

Results: In the nebivolol group after 1 month of study, the mean reduction in systolic blood pressure (SBP) was 134.2±3.07-118.26±4.66 and mean reduction in diastolic BP (DBP) was 87.13±1.87-80.73±1.99. Reduction in SBP and DBP in the nebivolol group was significant (p≤0.0001). In the placebo, and atenolol group results were not significant.

Conclusion: Nebivolol produces a significant reduction in SBP and DBP in pre-hypertensive patients. Atenolol and placebo did not show beneficial results.


Sit JW, Sijian L, Wong EM, Yanling Z, Ziping W, Jianqiang J, et al. Prevalence and risk factors associated with prehypertension: identification of foci for primary prevention of hypertension. J Cardiovasc Nurs. 2010;25(6):461-9.

Rafraf M, Gargari BP, Safaiyan A. Prevalence of prehypertension and hypertension among adolescent high school girls in Tabriz, Iran. Food Nutr Bull. 2010;31(3):461 5.

Saseen LL, Carter BL. Hypertension. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy. 6th Edition. New York: McGraw-Hill; 2005: 185-217.

Vasan RS, Larson MG, Leip EP, Evans JC, O’Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345(18):1291-7.

Godwin M, Pike A, Kirby A, Jewer C, Murphy L. Prehypertension and hypertension in a primary care practice. Can Fam Physician. 2008;54(10):1418-23.

Papadopoulos DP, Makris TK, Papademetriou V. Is it time to treat prehypertension?. Hypertens Res. 2008;31(9):1681-6.

Celik T, Iyisoy A, Acikel C, Yuksel C, Celik M, Yaman H, et al. The comparative effects of metoprolol and perindopril on aortic elasticity in young patients with prehypertension. Blood Press Monit. 2008;13(3):169-76.

Westfall TC, Westfall DP. Adrenergic agonists and antagonists. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. 11th Edition. New York: McGraw-Hill; 2006: 237-95.

Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation. 2001;104(5):511-4.

Parenti A, Filippi S, Amerini S, Granger HJ, Fazzini A, Ledda F. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol. J Pharmacol Exp Ther. 2000;292(2):698-703.

Ritter JM. Nebivolol: endothelium-mediated vasodilating effect. Cardiovasc Pharmacol. 2001;38 Suppl 3:S13-6.




How to Cite

Arya, R. K., & Jain, D. K. (2017). A study of atenolol and nebivolol in prehypertension. International Journal of Basic & Clinical Pharmacology, 3(5), 866–869. Retrieved from https://www.ijbcp.com/index.php/ijbcp/article/view/1118



Original Research Articles